Clear Creek Independent School District

Company Overview

Business Model: Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The company's approach leverages synthetic lethality, developing small molecule inhibitors designed to exploit specific genetic mutations in cancer cells to maximize effectiveness and minimize side effects on healthy tissue. Its primary focus is on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways.

Market Position: Aprea Therapeutics, Inc. aspires to be a leader in the emerging field of synthetic lethality-based precision oncology therapeutics. The company operates in a highly competitive pharmaceutical and biotechnology industry characterized by rapidly advancing technologies. While it believes its product candidates and scientific knowledge provide competitive advantages, it faces significant competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies with greater financial resources and expertise.

Recent Strategic Developments:

• Pipeline Shift: Following the acquisition of Atrin Pharmaceuticals Inc. in May 2022, Aprea Therapeutics, Inc. shifted its primary focus from mutant p53 tumor suppressor protein-related therapeutics to assets acquired from Atrin Pharmaceuticals Inc. and internally developed programs targeting DDR pathways.
• APR-1051 Advancement: The investigational new drug (IND) application for APR-1051 went into effect in March 2024, and the first patient was enrolled in the Phase 1 ACESOT-1051 dose escalation study in Q2 2024. As of March 2, 2026, enrollment is in cohort 8 (220 mg once daily). Preliminary results show early clinical proof-of-concept with a potential dose-response trend and two unconfirmed partial responses (uPRs) in PPP2R1A-mutated endometrial cancer patients (150 mg and 220 mg dose levels).
• ATRN-119 Development: The recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 monotherapy was determined in October 2025. The company has paused further enrollment in monotherapy arms of the ABOYA-119 study to explore combination approaches, including with radiation in HPV+ head and neck cancer, I/O agents, and antibody-drug conjugates (ADCs), based on preclinical data.
• Early-Stage Program: APR-1602, a macrocyclic DYRK1A/B inhibitor, is expected to enter IND-enabling studies in Q4 2026.

Geographic Footprint: Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, U.S. Its clinical trials for APR-1051 are actively enrolling at three sites in the U.S. with additional sites planned. The company has wholly-owned subsidiaries Aprea Therapeutics AB (Sweden), Aprea US, Inc., and ATR Pharmaceuticals LLC.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 100.0% (based on grant revenue)
• Operating Margin: -4420.0%
• Net Margin: -4200.0%

Investment in Growth:

• R&D Expenditure: $7.0 million (2333.3% of revenue)
• Capital Expenditures: $0 million
• Strategic Investments: The company's primary investment is in its clinical and preclinical pipeline, with a shift in focus following the May 2022 acquisition of Atrin Pharmaceuticals Inc.

Business Segment Analysis

Aprea Therapeutics, Inc. operates as a single reporting segment. However, R&D expenses are tracked by product candidate.

APR-1051 (WEE1 Inhibitor)

Financial Performance:

• Revenue: Not applicable (no product sales)
• R&D Expense: $2.6 million (-22.8% YoY)
• Key Growth Drivers:
  • Currently in Phase 1 dose escalation study (ACESOT-1051) for advanced solid tumors.
  • Preliminary clinical proof-of-concept observed with a potential dose-response trend across 70 mg, 100 mg, 150 mg, and 220 mg cohorts.
  • Two unconfirmed partial responses (uPRs) observed in patients with PPP2R1A-mutated uterine serous carcinoma/endometrial cancer at 150 mg and 220 mg dose levels.
  • Five additional patients achieved stable disease in earlier cohorts, including a 5% tumor reduction in HPV+ HNSCC and a 15% reduction in FBXW7-mutated colon cancer.
  • Safe and well-tolerated to date, supporting a potentially improved therapeutic index compared to competitor WEE1 inhibitors.

Product Portfolio:

• Lead WEE1 inhibitor product candidate.
• Designed to target WEE1 kinase, a key regulator of the cell cycle, exploiting genetic mutations in PPP2R1A, FBXW7, or increased Cyclin E1 (CCNE1) expression.

Market Dynamics:

• WEE1 has been clinically validated as a target.
• Competitors include Zentalis Pharmaceuticals, Debiopharm, IMPACT Therapeutics, Schrodinger, and Acrivon Therapeutics.
• APR-1051 aims to differentiate through its molecular structure, high selectivity for WEE1 over PLK family kinases, and potential absence of QT prolongation.

ATRN-119 (Mosipasertib) (ATR Inhibitor)

Financial Performance:

• Revenue: Not applicable (no product sales)
• R&D Expense: $3.2 million (-13.1% YoY)
• Key Growth Drivers:
  • Completed dose escalation in ABOYA-119 Phase 1/2a study, determining RP2D of 1,100 mg once daily.
  • Favorable tolerability profile with manageable adverse events and preliminary signs of clinical activity in biomarker-defined patient populations.
  • Durable disease stabilization observed in heavily pretreated patients.
  • Dose-proportional pharmacokinetics.
  • Strategic focus shifted to combination approaches with DNA-damaging agents (radiation therapy, ADCs) and immune checkpoint inhibitors, based on preclinical synergy (e.g., with olaparib in BRCA2-deficient ovarian cancer). Monotherapy enrollment paused.

Product Portfolio:

• Oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase.
• First oral macrocyclic ATR inhibitor to enter clinical trials, designed for increased selectivity and potentially improved tolerability.

Market Dynamics:

• ATR inhibition is an attractive therapeutic approach for cancers with DDR pathway deficiencies.
• Competitors include Artios Pharma, AstraZeneca, IMPACT Therapeutics, Merck KGaA, and Xeno Therapeutics.
• ATRN-119 aims to differentiate through its macrocyclic structure, high selectivity for ATR over related PIKK kinases (ATM, DNA-PK, mTOR), and favorable tolerability.

APR-1602 (DYRK1 Inhibitor)

Financial Performance:

• Revenue: Not applicable (no product sales)
• R&D Expense: Included in "Other early-stage development programs" ($0.1 million, -53.0% YoY).
• Key Growth Drivers:
  • Early-stage preclinical program.
  • Macrocyclic DYRK1A/B inhibitor.
  • Expected to enter IND-enabling studies in Q4 2026.

APR-246 (eprenetapopt) (p53 Reactivator)

Financial Performance:

• Revenue: Not applicable (no product sales)
• R&D Expense: $13,279 (-13.3% YoY)
• Key Growth Drivers:
  • No ongoing clinical trials.
  • Primary focus shifted away from this program due to Phase 3 trial failure and clinical holds by the FDA in 2021 and 2022.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None in 2025.
• Dividend Payments: Aprea Therapeutics, Inc. has never declared or paid cash dividends and does not expect to in the foreseeable future.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $14.6 million
• Total Debt: Not explicitly stated, but no significant long-term debt is indicated.
• Net Cash Position: Approximately $14.6 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not disclosed.

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(12.9) million
• Free Cash Flow: $(12.9) million (Operating Cash Flow - Capital Expenditures of $0 million)
• Cash Conversion Metrics: Not explicitly provided.

Operational Excellence

Production & Service Model: Aprea Therapeutics, Inc. operates a contract manufacturing model. It does not own or operate cGMP manufacturing facilities and has no current plans to build its own. The company contracts with third parties for the manufacture of product candidates for preclinical studies and clinical trials, including raw materials and consumables, consistent with cGMP requirements. Company personnel and consultants oversee these contract manufacturers.

Supply Chain Architecture: Key Suppliers & Partners:

• Active Pharmaceutical Ingredients (APIs) & Drug Products: Currently relies on a single contract manufacturer for APR-1051 and ATRN-119 APIs and drug products. The company believes this manufacturer has sufficient capacity for current demand and that alternative sources exist if needed.
• Clinical Research Organizations (CROs): Relies on CROs, clinical data management organizations, medical institutions, and clinical investigators to conduct clinical trials and some aspects of research and preclinical studies.
• MD Anderson Cancer Center: Translational research collaboration for APR-1051.

Facility Network:

• Manufacturing: No owned manufacturing facilities. Relies on third-party contract manufacturers.
• Research & Development: Utilizes a facility in Doylestown, Pennsylvania, consisting of approximately 1,550 square feet of office and laboratory space.
• Distribution: Relies on third parties to store and distribute drug supplies for clinical trials.

Operational Metrics: No specific operational metrics (e.g., capacity utilization, efficiency measures) are disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Aprea Therapeutics, Inc. currently has no products approved for sale and therefore no established go-to-market strategy. If product candidates receive marketing approval, the company may develop its own sales and marketing organization or enter into collaborations with third parties for these functions.

Customer Portfolio: Not applicable, as the company has no commercial products.

Geographic Revenue Distribution:

• The company's revenue is primarily generated through grants from government and non-government organizations, not product sales. No geographic breakdown of grant revenue is provided.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industries, particularly the cancer drug sector, are highly competitive. They are characterized by rapidly advancing technologies, evolving understanding of disease etiology, and a strong emphasis on proprietary drugs.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• WEE1 Inhibitors (APR-1051): Zentalis Pharmaceuticals, Debiopharm, IMPACT Therapeutics, Schrodinger, Acrivon Therapeutics. AstraZeneca previously developed AZD-1775 but discontinued development.
• ATR Inhibitors (ATRN-119): Artios Pharma, AstraZeneca, IMPACT Therapeutics, Merck KGaA, Xeno Therapeutics (formerly Repare Therapeutics’ ATR inhibitor program).
• General Cancer Treatments: Major pharmaceutical, specialty pharmaceutical, and biotechnology companies developing or marketing treatments for cancer, including surgery, radiation, and various drug/biologic therapies.

Emerging Competitive Threats: The industry faces continuous threats from new entrants, disruptive technologies, and alternative solutions. Competitors may develop safer, more effective, more convenient, or less expensive drugs, or obtain regulatory approval more rapidly.

Competitive Response Strategy: Aprea Therapeutics, Inc. aims to maintain competitive advantage through the development of potentially best-in-class product candidates with differentiated profiles (e.g., APR-1051's selectivity and therapeutic index, ATRN-119's macrocyclic structure and combination potential) and by identifying opportunities for combination therapies.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive industry, rapidly advancing technologies, evolving disease understanding. Potential for competitors to develop superior or cheaper drugs, or gain approval faster.
• Technology Disruption: Reliance on synthetic lethality, an emerging strategy; negative perceptions or adverse events in this class could impact development and approval.
• Customer Concentration: Not applicable for commercial products, but patient enrollment in clinical trials is a risk.
• Product Commercialization: No products approved for sale; future success depends on obtaining marketing approval and achieving market acceptance, which is uncertain.
• Pricing & Reimbursement: Potential for unfavorable pricing regulations, third-party coverage limitations, and healthcare reform initiatives to reduce profitability.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Reliance on a single third-party contract manufacturer for API and drug product for lead candidates. Any failure could delay development or commercialization.
• Clinical Trial Execution: Limited experience as a company in conducting large-scale clinical trials; reliance on third parties (CROs, investigators) introduces risks of delays, non-compliance, or unsatisfactory performance.
• Managing Growth: Expected growth in employees and operations may be difficult to manage effectively, potentially disrupting business plans.
• Employee Misconduct: Risk of employees or consultants engaging in fraud or non-compliance with regulatory standards.
• IT System Failures & Cybersecurity: Reliance on IT systems and third-party vendors, exposing the company to risks of cyberattacks, data breaches, and system disruptions, which could compromise sensitive information and operations.

Financial & Regulatory Risks

• Financial Position: Significant accumulated losses ($333.6 million as of Dec 31, 2025) and expectation of continued losses.
• Need for Additional Capital: Existing cash and cash equivalents (including January 2026 private placement proceeds) are projected to fund operations only into Q1 2027, raising substantial doubt about the company's ability to continue as a going concern.
• Regulatory Approval Uncertainty: Marketing approval process is expensive, time-consuming, and uncertain; no guarantee of approval for any product candidate.
• Post-Approval Requirements: Approved products will be subject to ongoing regulatory requirements, post-marketing studies, and potential restrictions, with non-compliance leading to penalties or withdrawal.
• Tax Matters: Significant deferred tax assets ($56.3 million) with a full valuation allowance, dependent on future taxable income. Potential limitations on net operating loss carryforwards due to ownership changes (e.g., Section 382).

Geopolitical & External Risks

• Geopolitical Exposure: Global economic uncertainty, geopolitical conflicts (e.g., Russia/Ukraine, Middle East), and trade tensions (e.g., U.S.-China tariffs) could adversely affect business, financial condition, and supply chain.
• Natural & Man-made Disasters: Exposure to natural disasters and other business disruptions (e.g., extreme weather, infrastructure failure) could disrupt operations.
• Government Agency Disruptions: Funding shortages, shutdowns, or policy changes at regulatory agencies (FDA, SEC) could delay product development and approval.

Innovation & Technology Leadership

Research & Development Focus: Aprea Therapeutics, Inc. is focused on precision oncology through synthetic lethality, specifically targeting DNA damage response (DDR) pathways. Its R&D efforts involve integrated discovery technologies and expertise in small molecule drug discovery to identify novel targets and patient populations.

Core Technology Areas:

• WEE1 Kinase Inhibition: Development of APR-1051, a highly potent and selective WEE1 inhibitor.
• ATR Kinase Inhibition: Development of ATRN-119 (Mosipasertib), a novel oral macrocyclic ATR inhibitor.
• DYRK1A/B Inhibition: Early-stage preclinical program with APR-1602.

Innovation Pipeline:

• Clinical Stage: APR-1051 (WEE1 inhibitor, Phase 1), ATRN-119 (ATR inhibitor, Phase 1/2a, exploring combinations).
• Preclinical Stage: APR-1602 (DYRK1A/B inhibitor, ready for IND-enabling studies in Q4 2026).

Intellectual Property Portfolio (as of December 31, 2025):

• DDR Inhibitors (ATR and WEE1 programs): 4 issued U.S. patents, 2 U.S. patent applications, 30 pending non-U.S. patent applications (including 1 International patent application), and 22 non-U.S. patents. Claims cover composition of matter, pharmaceutical compositions, and methods of use. Expected expiration between 2035 and 2045.
• p53 Reactivators (eprenetapopt): 3 issued U.S. patents, 1 pending U.S. application, and approximately 80 foreign issued patents. Claims cover drug product formulations and methods of use. Expected expiration between 2031 and 2040. The chemical structure of eprenetapopt is in the public domain, so no composition of matter patents are owned or licensed for this compound.
• Patent Strategy: Seeks patent protection for composition of matter, methods-of-use, formulations, and manufacturing processes. Also relies on trade secrets and confidentiality agreements.

Technology Partnerships:

• MD Anderson Cancer Center: Collaboration for translational research on APR-1051, supporting its potential as a single agent and in immunotherapy combinations for HPV+ head and neck squamous cell carcinoma (HNSCC).

Leadership & Governance

Executive Leadership Team (as of December 31, 2025)

Leadership Continuity: The company is highly dependent on its key scientific, technical, and senior management personnel, including Dr. Gilad and Mr. Hamill. Recruiting and retaining qualified personnel is critical to success.

Board Composition: The filing lists the names of the directors but does not provide details on their independence, expertise areas, or committee structure.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 8 full-time employees.
• Skill Mix: 5 employees directly engaged in research and development; the rest provide administrative, business, and operations support. The company also utilizes outside consultants and independent contractors.

Talent Management:

• Acquisition & Retention: Objectives include identifying, recruiting, retaining, incentivizing, and integrating employees. The company provides competitive salaries, bonuses, opportunities for equity ownership (through the 2019 Equity Incentive Plan), and a robust benefits package.
• Employee Value Proposition: Includes competitive salaries and bonuses, stock awards, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and flexible work schedules.

Diversity & Development: The company provides development programs for continued learning and growth. Specific diversity metrics are not disclosed.

Environmental & Social Impact

Environmental Commitments: Aprea Therapeutics, Inc. states it is compliant in all material respects with applicable environmental laws. It does not anticipate that such compliance will have a material effect on capital expenditures, earnings, or its competitive position. The company's operations involve hazardous and flammable materials, which are disposed of by third parties.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: Not applicable, as the company has no commercial products and generates revenue primarily from grants.

Economic Sensitivity: The company's operations and financial condition are sensitive to general conditions in the global economy, geopolitical conflicts, and disruptions in financial markets, which could impact funding availability and costs.

Industry Cycles: The pharmaceutical and biotechnology industries are characterized by long and uncertain development cycles.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Aprea Therapeutics, Inc. is subject to extensive regulation by government authorities in the United States (e.g., FDA) and other countries regarding the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring, and import/export of drug products.

Industry-Specific Regulations:

• Drug Development & Approval: Federal Food, Drug, and Cosmetic Act (FDCA), Investigational New Drug (IND) application, New Drug Application (NDA), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), current Good Manufacturing Practice (cGMP).
• Exclusivity: Hatch-Waxman Act (five-year New Chemical Entity (NCE) data exclusivity, three-year marketing exclusivity), Orphan Drug Act (seven-year orphan product exclusivity).
• Expedited Programs: Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval pathways.
• Pediatric Research Equity Act: Requirements for pediatric data.

Trade & Export Controls:

• Anti-Bribery & Anti-Corruption: Foreign Corrupt Practices Act (FCPA) and similar international laws.
• Export Restrictions: Applicable import and export control regulations, economic sanctions (e.g., Office of Foreign Assets Control of the U.S. Department of the Treasury), anti-money laundering laws, customs requirements, and currency exchange regulations.

Legal Proceedings: Aprea Therapeutics, Inc. was not subject to any material legal proceedings during 2025 and 2024, and no material legal proceedings are currently pending or threatened.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for 2025 and 2024 due to operating losses.
• Deferred Tax Assets: Total gross deferred tax assets of $56.3 million as of December 31, 2025, primarily from net operating loss carryforwards ($48.6 million). A full valuation allowance of $56.3 million has been provided due to uncertainty of realization.
• Net Operating Loss (NOL) Carryforwards: $143.3 million (foreign), $85.4 million (federal), and $91.8 million (state) as of December 31, 2025, expiring at various dates through 2037.
• Section 382 Limitations: Certain NOL carryforwards may be subject to limitations under Internal Revenue Code Section 382 (U.S.) or similar provisions (Sweden) due to potential ownership changes. The company believes the May 2022 acquisition of Atrin Pharmaceuticals Inc. likely resulted in an ownership change under Section 382.
• Uncertain Tax Positions: Approximately $0.1 million in liabilities related to uncertain tax positions as of December 31, 2025 and 2024.

Geographic Tax Planning: The company files tax returns in Sweden, the United States, Massachusetts, and Pennsylvania.

Tax Reform Impact:

• Tax Cuts and Jobs Act of 2017 (TCJA): Impacted corporate tax rate, deductibility of net interest, base erosion and anti-abuse minimum tax, and Global Intangible Low-Taxed Income (GILTI).
• CARES Act: Amended TCJA regarding NOL deductions.
• One Big Beautiful Bill Act (OBBBA) (July 2025): Made changes to U.S. tax code including 100% bonus depreciation, immediate deduction of domestic R&D costs, and more favorable interest expense deduction rules. The company determined an immaterial impact on consolidated financial results.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Holds clinical trial liability insurance coverage up to $5.0 million. Carries insurance for cyber events.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.